Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

Vortioxetine; Placebo

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder

Номер протоколаLuAA21004_311
ФазаФаза III
Участников по плану — во всех странах исследования301
Сроки01.09.2008 — 01.07.2009
Начало: 1 сентября 2008Окончание: 1 июля 2009
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00744627/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 301 чел. во всех странах исследования.
  • Плановая дата окончания (07.2009) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 37

Критерии включения

  • Suffers from a primary diagnosis of Generalized Anxiety Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.
  • Has a Hamilton Anxiety Scale total score ≥20 at Screening and Baseline.
  • Has a Hamilton Anxiety Scale score ≥2 on both Item 1 (anxious mood) and Item 2 (tension) at Screening and Baseline.
  • Has a Montgomery-Åsberg Depression Rating Scale total score ≤16 at Screening and Baseline.
  • Male and females of childbearing potential who are sexually active agree to use adequate contraception from Screening throughout the duration of the study and for 1 month after the last dose of study medication.

Критерии невключения

  • Has received any investigational compound <30 days before Screening or 5 half-lives prior to Screening.
  • Has received Lu AA21004 in a previous clinical study or as a therapeutic agent.
  • Has 1 or more of the following:
  • Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the DSM-IV-TR.
  • Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
  • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
  • Presence or history of a clinically significant neurological disorder (including epilepsy).
  • Neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington disease, etc).
  • Any Axis II disorder that might compromise the study.
  • Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study including:
  • Nonsteroidal anti-inflammatory drugs
  • Rifampin
  • Macrolide antibiotics
  • Hormones
  • Hypoglycemic agents and Insulin
  • Systemic steroids
  • Antineoplastics
  • Antiobesity agents
  • Antidiarrheal agents (episodic use allowed)
  • Antifungal agents (episodic topical use allowed)
  • Antihistamines (episodic use of loratadine, desloratadine, cetirizine allowed)
  • Cough/cold agents (episodic use allowed but preparations containing pseudoephedrine and narcotics are NOT allowed)
  • Diuretics (episodic use allowed)
  • Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
  • Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
  • Has received electroconvulsive therapy within 6 months prior to Screening.
  • Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
  • Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.
  • Has an alanine aminotransferase, aspartate aminotransferase or bilirubin level >1.5 times the upper limits of normal.
  • Has a serum creatinine of >1.5 times the upper limits of normal.
  • Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those participants with basal cell or stage I squamous cell carcinoma of the skin.
  • Has clinically significant abnormal vital signs as determined by the investigator.
  • Has 1 or more laboratory values outside the normal range, based on the blood or urine samples taken at Screening, that are considered by the investigator to be clinically significant.
  • Has thyroid stimulating hormone value outside the normal range at Screening and is deemed clinically significant by the investigator.
  • Has an abnormal electrocardiogram as determined by the central reader and confirmed as clinically significant by the investigator.
  • Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  • Has previously participated in this study.

Источник: ClinicalTrials.gov, NCT00744627 · запись обновлена в реестре 3 марта 2014.

Дизайн и результаты

ДизайнРандомизированное, четверное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)301
Что измеряют — первичные конечные точки (1), вторичных — 24
  • Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 — Baseline to Week 8

Цель исследования

The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00744627 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.